Phenotyping cardiomyocytes derived from iPS Cells

诱导性多能干细胞（iPSC）从分化的体细胞如真皮细胞的发育 大约8年前，成纤维细胞彻底改变了生物学和医学的许多领域。的发现 这项技术让山中伸弥在2012年获得了诺贝尔奖，并产生了令人难以置信的 科学的奋进，因为它是第一次出版。iPSC可以分化成许多不同的细胞类型， 仍然保持与原始供体细胞相同的基因型。在本提案中，我们将与 StemCell Technologies Inc.一家位于温哥华的私人生物技术公司， 转化为心肌细胞，并对所得细胞进行表型分析，以确保它们具有心肌细胞的许多特性。 功能和成熟的心肌收缩细胞。实验将集中在新开发的复杂的 技术来表征细胞，以确保它们已被重新编程为心脏细胞，或 心肌细胞

The development of inducible pluripotent stem cells (iPSCs) from differentiated somatic cells such as dermal fibroblasts about 8 years ago has revolutionized many fields of biology and medicine. The discovery of the technique to make this possible won Shinya Yamanaka the Nobel prize in 2012 and has spawned an incredible scientific endeavor since it was first published. iPSCs can be differentiated into many different cell types and still remain the same genotype as the origin donor cells. In this proposal we will, in collaboration with StemCell Technologies Inc. a privately-owned biotechnology company based in Vancouver, differentiate cells into cardiomyocytes and phenotype the resultant cells to ensure that they possess many of the properties of functioning and mature cardiac contractile cells. The experiments will focus on newly developed sophisticated techniques to characterize the cells to ensure that they have been reprogrammed to become heart cells or cardiomyocytes.